Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Revenue for 7 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 61.18% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.2 million through Dec 2025, down 16.7% year-over-year, with the annual reading at $39.2 million for FY2025, 16.7% down from the prior year.
  • Revenue for Q4 2025 was $2.9 million at Kymera Therapeutics, up from $2.8 million in the prior quarter.
  • The five-year high for Revenue was $47.9 million in Q4 2023, with the low at $2.8 million in Q3 2025.
  • Average Revenue over 5 years is $14.2 million, with a median of $11.5 million recorded in 2022.
  • The sharpest move saw Revenue skyrocketed 463.23% in 2021, then tumbled 84.56% in 2024.
  • Over 5 years, Revenue stood at $15.3 million in 2021, then rose by 5.66% to $16.1 million in 2022, then skyrocketed by 196.7% to $47.9 million in 2023, then crashed by 84.56% to $7.4 million in 2024, then crashed by 61.18% to $2.9 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $2.9 million, $2.8 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.